RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• HER2 is a key biomarker for HER2-targeted therapies.
• Antibody-drug conjugates (ADCs) like trastuzumab emtansine (T-DM1) use HER2 as a cellular entry point for cytotoxic agents.
• ADC efficacy may depend on intracellular drug transport mechanisms, suggesting complex biomarker requirements.

Purpose of the Study:

• To investigate potential biomarkers for T-DM1 sensitivity beyond HER2.
• To explore the role of intracellular trafficking proteins in ADC response.
• To identify novel predictive biomarkers for antibody-drug conjugate therapies.

Main Methods:

• Assessed correlation between RAB5A expression and T-DM1 sensitivity in five HER2-positive cell lines.
• Validated RAB5A expression and T-DM1 sensitivity correlation in patient cohorts from the I-SPY2 and KAMILLA clinical trials.
• Compared findings in patients treated with T-DM1/pertuzumab versus trastuzumab/paclitaxel.

Main Results:

• A positive correlation was observed between early endosome marker RAB5A and T-DM1 sensitivity in HER2-positive cell lines.
• This correlation was confirmed in breast cancer patients receiving T-DM1/pertuzumab in the I-SPY2 trial.
• The clinical correlation was further validated in patients from the KAMILLA trial, but not in the trastuzumab/paclitaxel control arm.

Conclusions:

• RAB5A is a potential predictive biomarker for T-DM1 response in HER2-positive breast cancer.
• Proteins involved in endocytic trafficking represent promising predictive biomarkers for ADCs.
• This research expands the understanding of ADC mechanisms and biomarker development.